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Abstract: The aim of the observational pharmaco-epidemiological study Optimax II was to 
seek whether the pre-existence of a metabolic syndrome (MS) deﬁ  ned by the NCEP-ATP III 
criteria impacts blood pressure (BP) control in hypertensive patients receiving a ﬁ  xed perin-
dopril/indapamide combination therapy. The primary objective of the study was to compare 
in patients with and without MS the rate of BP control deﬁ  ned as a systolic BP  140 mmHg 
and a diastolic BP  90 mmHg. Patients were prospectively included and the follow-up lasted 
6 months. The study population consisted of 24,069 hypertensive patients (56% men; mean age 
62 ± 11 years; 18% diabetics; mean BP at inclusion 162 ± 13/93 ± 9 mmHg). MS was found in 
30.4% of the patients (n = 7322): 35.2% women and 20.1% men. Three therapeutic subgroups 
were constituted: Group A, previously untreated, received the combination therapy as initial 
treatment; Group B, previously treated but with unsatisfactory results and/or treatment intoler-
ance, had its previous treatment switched to perindopril/indapamide; and Group C, previously 
treated, with good treatment tolerance but uncontrolled BP, received the study treatment in 
adjunction to the previous one. The normalization rate was 70.3% in group A, 68.4% in Group 
B, and 64.1% in Group C (p   0.0001). The pre-existence of MS did not show any signiﬁ  cant 
inﬂ  uence on these rates since BP lowering was –22.7 ± 13.7 (SBP) and –12.0 ± 10.0 mmHg 
(DBP) in patients without MS and –22.6 ± 13.3 (SBP) and −12.1 ± 9.7 (DBP) in those with 
MS. The results of this study show a signiﬁ  cant effect of perindopril/indapamide treatment on 
systolic BP lowering, whatever the treatment status: initiation, switch, or adjunctive therapy, 
and independently from the presence or not of MS. This effect may be related to the speciﬁ  c 
vascular effect of the perindopril/indapamide combination, which has recently demonstrated in 
the ADVANCE trial its ability to reduce mortality, and cardiovascular and renal complications 
in diabetic patients.
Keywords: hypertension, metabolic syndrome, combination therapy, antihypertensive 
efﬁ  cacy
Introduction
The metabolic syndrome (MS) refers to a cluster of several features such as obesity, 
abnormal levels of blood lipids, pre-diabetes, and arterial hypertension, considered likely 
to induce a cardiovascular risk (Lakka et al 2002; Grundy et al 2004). Although known 
for about 20 years with the ﬁ  rst pathogenic description by Reaven in the Banting lecture 
(Reaven 1988), the pathogenesis that underlies the clustering of diverse cardiovascular risk 
factors is beginning to be better understood. Indeed, recent studies demonstrate a strong Vascular Health and Risk Management 2008:4(2) 444
Mourad et al
link between initial microvascular damage, hypertension, and 
insulin resistance (De Jongh et al 2004). Primitive capillary 
rarefaction contributes to both increased blood pressure (BP) 
and impaired target organ perfusion. This decrease in blood 
ﬂ  ow leads to impaired glucose uptake in muscle, contributing to 
increased insulin resistance (Reaven 1988; Julius et al 1991).
Many deﬁ  nitions have been proposed to identify MS 
(Alberti and Zimmet 1998; Expert Panel 2001; Alberti et al 
2005; Grundy et al 2005). None is clearly universal and the 
exact prevalence of MS in the general population has never 
been identiﬁ  ed, with ﬁ  gures that change from one country to 
another (Ford et al 2002; Tonkin 2003; Hu 2004), depend-
ing on the deﬁ  nition used (Day 2007; Nilsson et al 2007; 
Qiao et al 2007; Rodilla et al 2007). Results may also differ 
depending on the analyzed population, with differences 
observed to be in relation with ethnicity (Ajjan et al 2007), 
gender (Mitrakou 2006; Royer et al 2007), or other factors 
such as body mass index (Choi et al 2007) or age (Kelishadi 
2007). Nevertheless, among the various MS deﬁ  nitions, that 
of the National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP ATPIII) (Expert Panel 2001; Grundy 
et al 2005) seems to be somehow consensual. It deﬁ  nes MS as 
the existence of at least three out of the following ﬁ  ve criteria: 
glucose intolerance, high triglycerides (TG), low HDL level, 
arterial pre-hypertension, and abdominal obesity.
Overall, the prevalence of this disorder that is currently 
observed to increase (Borch-Johnsen 2007) is a real concern 
in terms of public health (Balkau and Charles 1999; Borch-
Johnsen 2007). In France, MS prevalence in the general 
population has been estimated to reach 9% (Hu 2004). Sev-
eral studies have analysed the prognostic value of MS (Lakka 
et al 2002), in particular among hypertensive populations 
(Schillaci et al 2004; Navarro et al 2007); they showed a 
signiﬁ  cant increase in the occurrence of cardiovascular events 
in those patients with hypertension and MS, and a positive 
relationship between the incidence of cardiovascular events 
and the number of risk factors included in the MS (Schillaci 
et al 2004).
MS management is complex and multifocal; it combines 
non-pharmacologic measures and conventional pharmacologic 
treatment of the existent risk factors among which, due to 
the frequency of hypertension as one component of MS (Hu 
et al 2004), an antihypertensive therapy for BP normalization. 
Most recent international therapeutic guidelines recommend 
combination therapies using low doses of antihypertensive 
agents (ESC-ESH Guidelines 2007).
Whether the presence of MS has an impact on the thera-
peutic efﬁ  cacy of an antihypertensive regimen has never been 
studied. The present pharmaco-epidemiologic observational 
study (OPTIMAX 2) has been conducted to identify potential 
relationships between the presence of MS in a population 
of hypertensive patients and the therapeutic results of an 
antihypertensive treatment implemented as recommended 
by the guidelines.
Methods
This observational study with a prospective inclusion of 
patients and 3–6 months of routine follow-up was carried 
out with the collaboration of either general practitioners, 
or community or hospital cardiologists. The investigators 
sample was randomly constituted, and stratiﬁ  ed according 
to the geographic area of medical practice.
The primary objective of the study was to measure and 
compare the rate of BP normalization in hypertensive patients 
receiving a low-dose combined antihypertensive therapy 
(ﬁ  xed-dose ACE inhibitor + diuretic (perindopril/indap-
amide)) according to the presence or absence of associate 
MS. Secondary objectives were the evaluation of the rate 
of BP normalization among the study population according 
to the number of identiﬁ  ed risk factors, and the rate of BP 
normalization according to one of the following clinical 
conditions that necessitate combination therapy: A. Initiation 
of the ﬁ  xed low-dose combination therapy in never-treated 
essential hypertensive patients (or patients having stopped 
their treatment for at least 3 months); B. Modiﬁ  cation of an 
ongoing antihypertensive treatment by treatment switch to 
the study bitherapy in uncontrolled already treated patients 
or patients experiencing adverse effects with their medica-
tion; and C. Optimization of the antihypertensive treatment 
by adjunction of the study bitherapy in an uncontrolled, 
already treated patient.
Normalization was considered achieved when systolic 
BP was  140 mmHg and diastolic BP  90 mmHg; optimal 
normalization was achieved when systolic BP was  140 
mmHg and diastolic BP  90 mmHg, with no signiﬁ  cant 
adverse side effects.
During the 2-month inclusion period, the investigators 
were asked to include the successive 6 patients who met the 
inclusion criteria, with, preferentially 2 adult ( 18 years) 
patients corresponding to each of the clinical situations 
described above. Inclusion criteria were those that justify 
the treatment in the therapeutic groups A, B, and C. Exclu-
sion criteria were pregnancy in women, unavailability of the 
biological data necessary to ascertain the existence of MS, 
potential non-assiduity or impossibility to attend the follow-
up visit, participation in another study.Vascular Health and Risk Management 2008:4(2) 445
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Data collection was carried out by a medical questionnaire 
completed by the investigator at the inclusion visit: age, gen-
der, blood pressure (average of 2 BP measures separated by 
a 10-min interval), waist circumference, height, weight, bio-
chemistry (TG, total cholesterol, HDL- and LDL-cholesterol, 
fasting glucose), ongoing metabolic and antihypertensive 
treatments, daily dosages, and the new antihypertensive 
therapy instituted according to the A, B, or C therapeutic 
situation. Then, 3–6 months after inclusion, another medical 
questionnaire was completed by the investigator to assess 
both efﬁ  cacy and safety of the study treatment. Follow-up and 
treatment modalities were deﬁ  ned by the investigator.
MS was deﬁ  ned as the existence of at least three of the 
following criteria: fasting plasma glucose  6.1 mmol/L; 
triglycerides level  1.7 mmol/L and/or ongoing treatment; 
low HDL deﬁ  ned as a blood concentration  1.04 mmol/L in 
men and  1.30 mmol/L in women; arterial pre-hypertension 
deﬁ  ned by a systolic BP  130 mmHg and diastolic BP 
 85 mmHg and/or ongoing antihypertensive treatment; and 
abdominal obesity deﬁ  ned as a waist circumference  102 cm 
in men and  88 cm in women.
Statistical analysis
Descriptive statistics are provided for the whole included 
population and by subgroups of patients deﬁ  ned according to 
the clinical situation (A, B, C as described above). Qualitative 
variables are presented as the number of patients by analyzed 
modality, and the corresponding percentage. Quantitative 
variables are expressed by the number of subjects, means ± 
standard deviation (SD), extreme values and, when neces-
sary, median values and quartiles. In comparative analyses, 
the level of statistical signiﬁ  cance was set at 5%.
Normalization and optimal normalization rates were 
calculated and described overall and according to the fol-
lowing criteria: presence/absence of MS as deﬁ  ned by the 
NCEP-ATPIII; number of existent risk factors out of the ﬁ  ve 
included in this deﬁ  nition; hypertension type at inclusion 
(systolic, diastolic, systolo-diastolic); tobacco consumption; 
history of peripheral arterial disease or type 1 or 2 diabetes; 
the therapeutic subgroup independently from the existence 
of associate MS; and identity of the antihypertensive therapy 
introduced at inclusion (ACE inhibitor/ diuretic agent or 
β-blocker/diuretic agent).
The prevalence of hypertension-related risk cofactors 
(target organ lesion such as left ventricular hypertrophy or 
renal failure; direct familial history of hypertension, cardio-
vascular disease or sudden cardiac death; and personal history 
of cardiovascular events such as stroke, myocardial infarction, 
angina, coronary revascularization, heart failure, peripheral 
artery disease, diabetes) was also calculated.
Between-group comparisons of the results were per-
formed using Chi² tests; in case such tests could not be 
performed, a Fisher’s exact test was carried out.
Efﬁ  cacy was analysed by comparison of BP values at 
inclusion and at the follow-up visit; in addition to overall 
efﬁ  cacy, this parameter was analyzed also by therapeutic 
subgroup and according to the presence or not of MS. The 
comparison of BP evolution between the subgroups was car-
ried out using a monofactorial (subgroup) ANOVA analysis; 
in case of signiﬁ  cant difference, a t test was performed.
In order to identify the factors that could be predictive 
of BP normalization, in the two subgroups of normalized 
and non-normalized patients, the following factors were 
described: gender, age, blood pressure at inclusion, target 
organ lesion, history of cardiovascular events, tobacco con-
sumption, physical exercise, treatment prescribed at inclu-
sion, and treatment tolerance. Then, the two subgroups were 
compared using a univariate logistic regression analysis; 10% 
was the level of signiﬁ  cance to select a factor to be introduced 
in the multivariate analysis. The multivariate logistic regres-
sion analysis was carried out with the discriminating factors 
and the ﬁ  nal model was elaborated by the stepwise method 
in the Logistic procedure of SASTM. The odds ratios of the 
most discriminating factors were calculated to determine the 
proﬁ  le of normalized patients.
Results
Clinical characteristics of the study 
population
Of the 25,116 ﬁ  les obtained during the inclusion period, 
24,591 were considered suitable for analysis; after elimina-
tion of the 522 ﬁ  les with protocol deviations or missing data, 
24,069 (97.9%) patients with hypertension and aged at least 
18 years were conﬁ  rmed protocol compliant and assessed. 
Their main clinical characteristics at inclusion are displayed 
in Table 1. A signiﬁ  cant difference (p   0.0001) was observed 
for gender, with a slight majority of men (55.8% vs 44.1%; 
p   0.0001) in the total population, and for age, with patients 
younger in Group A (untreated) than in the two other groups. 
Except for these two parameters and a mild difference for 
BP level of untreated patients (slightly higher than in the 
two other groups), no signiﬁ  cant difference on these clinical 
characteristics was observed between groups at inclusion.
About 30% of study patients presented with MS in addi-
tion to their hypertension. Table 2 displays the incidence of Vascular Health and Risk Management 2008:4(2) 446
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MS among the study population; no signiﬁ  cant difference 
was observed between groups. The most frequent criterion 
associated with hypertension was abdominal obesity; although 
not reaching statistical signiﬁ  cance, this criterion, like HDL-
cholesterol, was observed predominantly in women.
Several hypertension-related cofactors of cardiovascu-
lar risk were evident in the study population, as shown by 
Figure 1. In the three groups, elevated values were found 
for some cofactors of cardiovascular risk such as a poor 
practice of physical exercise (about 71% of the patients), 
a familial history of arterial hypertension (about 45%), 
tobacco consumption (about 26%), and type 2 diabetes 
(about 17%). Statistical differences between groups were 
found on all parameters, with the highest values observed in 
Group C; age-adjusted and gender-adjusted analyses show 
also statistically signiﬁ  cant differences between Group A 
and Group C (p   0.0001) except for tobacco consumption. 
In the population distributed according to the presence or 
absence of MS, the prevalence of all hypertension-related 
cofactors of cardiovascular risk was signiﬁ  cantly raised in the 
subgroup with MS compared with patients without, except 
for stroke (Table 3).
Treatment effect
Before inclusion in the study, in Group B (non-normal-
ized treated patients with adverse effects necessitating 
treatment switch) the most frequent treatments were: 
calcium channel blockers (26.6%), diuretics (27.7 %), 
ACE inhibitors (26.2 %) and β-blockers (20%); 19% 
were under bitherapy while 4.1% were receiving 3 agents 
and 1% more than 3 drugs. In Group C (non normalized 
treated patients without adverse effects, necessitating 
adjunctive antihypertensive treatment) the most frequent 
treatments were: calcium channel blockers (48.9%), and 
β-blockers (44.6%); 28.7% of the patients were under 
bitherapy while 9.5% were receiving 3 agents and 2.4% 
more than 3 drugs.
During the follow-up period, the normalization rate 
was 70.3% in Group A, 68.4% in Group B and 64.1% 
in Group C (p   0.0001). Optimal control (normalized 
BP and no adverse effect) was obtained in 69.8% of the 
Group A, 67.9% of the Group B, and 63.7% of the Group 
C (p   0.0001).
In none of the three therapeutic groups did the presence 
of pre-existing MS have any inﬂ  uence on the normalization 
rate: 66.7% in patients with MS, and 68.4% in patients 
without (p = 0.52); optimal normalization rate was 66.4% in 
patients with MS and 67.7% in those without. The absence 
of any inﬂ  uence of MS on the lowering of BP was observed, 
whatever the number of factors that constitute the syndrome. 
As shown in Figure 2, when the population was distributed 
according to the presence or not of MS and by treatment 
Table 1 Descriptive clinical characteristics of the patients at inclusion, displayed for all patients and by treatment group. Except for 
age and gender, no signiﬁ  cant difference was observed between groups at inclusion
    Group A  Group B  Group C  All patients
   n  = 8,138 n  = 9,415 n  = 6,516 n  = 24,069
Gender*  %  men  58.0 52.9 57.1 55.8
Age* Mean  ± SD  58.2 ± 11.4  63.2 ± 11.2  64.4 ± 10.6  61.8 ± 11.4
Systolic BP (mmHg)  Mean ± SD  164.2 ± 12.0  159.1 ± 13.2  163.4 ± 12.1  162.0 ± 12.7
Diastolic BP (mmHg)  Mean ± SD  95.0 ± 8.6  91.7 ± 9.1  93.4 ± 9.2  93.3 ± 9.1
Triglycerides (mmol/L)  Mean ± SD  1.45 ± 0.71  1.46 ± 0.69  1.52 ± 0.73  1.47 ± 0.71
   1.7  mmol/L  %  23.3 23.7 27.2 24.5
Fasting glucose (mmol/L)  Mean ± SD  5.79 ± 1.35  5.91 ± 1.48  6.12 ± 1.62  5.93 ± 1.49
   6.1  mmol/L  %  26.0 30.3 36.2 30.5
Total cholesterol (mmol/L)  Mean ± SD  5.82 ± 1.01  5.72 ± 1.02  5.71 ± 1.06  5.75 ± 1.03
HDL-cholesterol (mmol/L)  Mean ± SD  1.35 ± 0.35  1.35 ± 0.36  1.32 ± 0.35  1.34 ± 0.36
 Men    1.04 mmol/L  %  18.7  19.3  22.7  20.0
 Women    1.30 mmol/L  %  30.0  30.8  32.1  30.9
LDL-cholesterol (mmol/L)  Mean ± SD  3.63 ± 0.90  3.52 ± 0.89  3.52 ± 0.91  3.56 0.90
Waist circumference (cm)  Mean ± SD  97.7 ± 13.6  98.0 ± 13.8  99.7 ± 14.1  98.4 ± 13.8
 Men    102 cm  %  44.8  45.7  51.1  46.9
 Women    88 cm  %  59.5  62.4  65.0  62.2
Weight (kg)  Mean ± SD  80.1 ± 15.0  79.7 ± 14.9  81.8 ± 15.4  80.4 ± 15.1
Height (cm)  Mean ± SD  169.0 ± 8.4  167.8 ± 8.3  168.3 ± 8.4  168.3 ± 8.4
Anti-diabetic  therapy  %  11.7 18.5 25.8 18.2
Lipid-lowering  therapy  %  28.8 42.4 53.7 40.8
*p   0.0001Vascular Health and Risk Management 2008:4(2) 447
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Table 2 Prevalence of metabolic syndrome among the study population as a whole and distributed by therapeutic group
  Group A  Group B  Group C  All patients
 n  = 8,138 n  = 9,415 n  = 6,516 n  = 24,069
Prevalence of metabolic syndrome  26.4%  30.7%  35.0%  30.4%
Fasting glucose   6.1 mmol/L  26.0%  30.3%  36.2%  30.5%
Triglycerides   1.7 mmol/L  23.3%  23.7%  27.2%  24.5%
Hypertensiona (raised BP or treatment)  100.0%  100.0%  100.0%  100.0%
HDL-cholesterol      
   1.04 mmol/L in men  18.7%  19.3%  22.7%  20.0%
   1.30 mmol/L in women  30.0%  30.8%  32.1%  30.9%
Waist circumference       
   102 cm in men  44.8%  45.7%  51.1%  46.9%
   88 cm in women  59.5%  62.4%  65.0%  62.2%
Number of MS criteria       
 1  criterion  39.7%  36.2%  32.8%  36.4%
 2  criteria  33.9%  33.1%  32.3%  33.2%
 3  criteria  17.2%  19.6%  21.9%  19.4%
 4  criteria  7.6%  8.7%  10.5%  8.8%
 5  criteria  1.7%  2.4%  2.5%  2.2%
aHypertension was a criterion for eligibility to the study. This is the reason why this parameter is quoted 100% in all groups.
Figure 1 Incidence of hypertension-related cofactors of cardiovascular risk in the study population distributed by therapeutic group. For all parameters, signiﬁ  cant differ-
ences (p   0.0001) were found between groups except for the familial history of hypertension (ns between Group A and Group B), and tobacco consumption (ns between 
Group B and Group C).
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group, signiﬁ  cant differences were found between the 
normalization rates of Group A, B, and C indicating an 
effect of the treatment independent from the pre-existence 
of MS.
In the total population, as in the three subgroups of 
patients, BP was significantly lowered after treatment 
(p   0.0001) (Figure 3). This BP control was especially 
marked for systolic BP which decreased signiﬁ  cantly from 
baseline in the whole group of patients (–22.7 ± 13.5 mmHg) 
and in each of the three groups: –25.5 ± 12.9 mmHg in Group 
A, –19.9 ± 13.7 mmHg in Group B, and –23.1 ± 13.2 mmHg 
in Group C (p   0.0001 for all).
Table 3 Incidence of hypertension-related cofactors of cardiovascular risk in the study population distributed according to the pres-
ence or absence of MS. For all parameters except personal history of stroke (equivalent incidence), signiﬁ  cant differences (p   0.001) 
were found between groups
  Patients without MS n = 16,747  Patients with MS n = 7,322 p  value
Target organ lesion    
Left ventricular hypertrophy  14.4%  21.5%   0.0001
Renal failure  3.8%  4.9%  0.0002
Direct familial history    
Arterial hypertension  42.8%  49.3%   0.0001
Cardiovascular disease or sudden death  15.0%  20.1%   0.0001
Personal history of cardiovascular disease    
Stroke 3.7%  3.6%  0.66
Myocardial infarction  2.8%  3.9%   0.0001
Angina 6.4%  10.6%   0.0001
Coronary revascularization  3.5%  4.6%   0.0001
Heart failure  2.6%  4.6%   0.0001
Peripheral arterial disease  6.5%  9.5%   0.0001
Type 1 diabetes  1.4%  4.0%   0.0001
Type 2 diabetes  10.1%  32.2%   0.0001
Tobacco consumption or cessation  1 year  26.7%  28.3%  0.0092
Irregular physical exercise  66.7%  80.8%   0.0001
Figure 2 Rates of BP control among the study patients distributed by treatment group and according to the presence or not of MS. No signiﬁ  cant difference was observed 
between the group of patients with MS vs the group of patients without MS (p = NS), but signiﬁ  cant differences were found between subgroups A, B, and C among the two 
patient groups “with MS” and “without MS”.
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Predictive factors of BP control
After the stepwise procedure, the factors selected as relevant 
for the elaboration of the logistic regression model were the 
gender, age class, SBP and DBP at inclusion, presence of 
left ventricular hypertrophy, diabetes and renal impairment, 
prescribed treatment and treatment tolerance. Those found 
to be signiﬁ  cantly correlated with adequate BP control were 
the female gender (OR: 1.200; 95% CI [1.122; 1.284]) and 
the absence of type 2 diabetes (OR: 1.120; 95% CI [1.025; 
1.224]), absence of left ventricular hypertrophy (OR: 1.235; 
95% CI [1.133; 1.346]) and absence of renal failure (OR: 
1.257; 95% CI [1.072; 1.473]). It was also observed that 
patients receiving a ﬁ  xed-dose bitherapy or a ﬁ  xed-dose 
bitherapy in addition to another monotherapy were more 
likely to have their BP reduced than patients receiving more 
than 3 treatments (respectively OR: 1.234; 95% CI [1.089; 
1.397] and OR: 1.196; 95% CI [1.050; 1.362]).
Treatment tolerance
Overall, the study treatment was well tolerated. Only 
2.3% of the included patients (n = 564) presented with 
a serious medical event. Main events reported among 
these patients were a necessity for hospitalization (0.7% 
in Group A, 0.9% in Group B, and 0.9% in Group C), 
and a cardiovascular event (0.4% in Group A, 0.7% in 
Group B, and 0.9% in Group C). At the end of follow-up, 
the vast majority of patients (81.8%) continued treatment 
with the low-dose perindopril/indapamide combination 
(2 mg/0.625 mg). In 11% of patients, the doses had to be 
increased to 4 mg/1.250 mg; the perindopril/indapamide 
combination was replaced by another treatment in 5.1% 
of patients and discontinued in 2.1% of patients.
Discussion
The ﬁ  ndings of the present observational study carried out 
with a very large sample of patients provide information on 
an aspect that has never been studied in hypertension: the 
potential inﬂ  uence of MS on the treatment action in terms of 
BP lowering. The most important result is that the presence 
of a pre-existing MS does not inﬂ  uence the antihypertensive 
effect of the treatment since BP was lowered to the same 
extent in both subgroups of patients without MS and patients 
with MS, whatever the number of factors that constitute the 
syndrome. Given either as initiation in untreated hypertensive 
patients, or as replacement or adjunctive therapy in those 
patients already treated but insufﬁ  ciently controlled or expe-
riencing adverse effects of their antihypertensive treatment, 
the ﬁ  xed low-dose antihypertensive combination used in this 
study achieved signiﬁ  cant BP reduction from baseline, and 
optimal BP control in 64%–70% of the patients.
Figure 3 BP lowering (difference from baseline) in the population as a whole and in the three subgroups of patients. Signiﬁ  cant differences were found both on the comparison 
between groups (p   0.0001 for all) and on BP difference from baseline (p   0.0001).
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Our results may not be discussed by comparing with 
other studies since none has studied the factors that may 
predict the BP response after treatment in hypertensive 
patients with MS and very few have speciﬁ  cally compared 
BP lowering between patients without MS and patients with 
MS – at least three of the ﬁ  ve determining traits. Reported 
results differ widely and there is a need for further research. 
A Spanish study has analyzed a large subset of patients 
(n = 6736) with MS deﬁ  ned according to the NCEP-ATPIII 
criteria; unlike our ﬁ  ndings, its results show that although 
hypertensive patients with MS were receiving more anti-
hypertensive medication than those without, the rate of BP 
control was lower in patients with MS (Barrios et al 2007). 
Despite the fact that further research is needed to conﬁ  rm the 
independence of the antihypertensive effect of the treatment 
therapy in hypertensive patients with MS, and to determine 
whether all medications used in hypertension display similar 
independence, our ﬁ  ndings are promising and show that a 
low-dose combination therapy given as recommended by 
the international guidelines may, in about 65%–70% of 
hypertensive patients with MS, control high blood pressure, 
one of the most frequently encountered components of MS 
(Hu et al 2004).
Our results show, in particular, signiﬁ  cant effects of 
the study treatment on systolic BP lowering, whatever the 
treatment status: initiation, switch, or adjunctive therapy, 
and independently from the presence or not of MS. This 
effect may be related to the speciﬁ  c vascular effect of the 
combination perindopril/indapamide on large arteries and 
microcirculation: this combined therapy was shown to restore 
both capillary density and large arterial compliance in hyper-
tensive patients (Asmar et al 2001; Levy et al 2001).
This vascular effect is likely to provide, in turn, a more 
selective SBP reduction and an improvement in coronary blood 
ﬂ  ow reserve (Mourad et al 2003; London et al 2004), two 
properties that contribute to a better target organ protection. As 
a matter of fact, the perindopril/indapamide combination has 
recently demonstrated in the ADVANCE trial, the largest trial 
ever carried out among diabetic patients, its ability to reduce 
cardiovascular and total mortality, as well as cardiovascular 
and renal complications (ADVANCE 2007).
This study displays also a body of epidemiologic charac-
teristics regarding that population of hypertensive patients 
who have also MS. The syndrome was screened among the 
study population using the NCEP-ATPIII criteria which are 
considered the simplest and the most commonly applied for 
MS detection (Mulè et al 2006). The incidence rate of MS 
among the hypertensive patients of our study is somewhat 
comparable to that found in other studies – although the 
criteria utilized to detect MS were not always those of the 
NCEP-ATPIII: about one third (Mulè et al 2005; Tamaki 
et al 2006; Ferrara et al 2007a, b). Some discrepan-
cies may be noticed, however, with lower reported rates 
(Leoncini et al 2005, 2007), higher (Garcia-Puig et al 
2006; Mulè et al 2007), and even far more elevated rates 
(Kelishadi et al 2005).
Among the reported hypertension-related cofactors of 
cardiovascular risk in patients with MS, the identiﬁ  cation of 
high rates of physical inactivity (81%) and tobacco consump-
tion (28% of the patients), signiﬁ  cantly higher than in patients 
without MS, suggest that much effort should be made for 
patient’s education since these two factors are the only ones 
that may be modiﬁ  ed by lifestyle changes. The other cardio-
vascular risk factors identiﬁ  ed that were all signiﬁ  cantly more 
frequent among MS patients than among MS-free patients 
conﬁ  rm that in hypertensive patients with MS, the cardiovas-
cular risk is signiﬁ  cantly raised. The prognostic value of MS 
among hypertensive populations has been studied in many 
studies (Schillaci et al 2004; Leoncini et al 2005; Mulè et al 
2005, 2006, 2007; Cuspidi et al 2007; Ferrara et al 2007a, b; 
Navarro et al 2007) that found a signiﬁ  cantly increased 
occurrence of cardiovascular complications and events in 
hypertensive patients with MS.
The results of the present study indicate a real need 
for metabolic screening in all hypertensive patients, and 
emphasize the importance of prevention in the management 
of hypertension which should focus on both BP lowering 
and correcting associated risk factors. MS associated with 
hypertension promotes organ damage and may, at least 
partly, explain the high cardiovascular morbidity and mor-
tality that is observed in hypertensive patients with MS. 
Controlling high BP should help in reducing this risk. This 
study shows that BP may be controlled in hypertensive 
patients with MS and that the presence of MS does not 
affect the action of the ﬁ  xed dose perindopril/indapamide 
combination which is well known for its cardiovascular 
protective effect in diabetic patients and given in compliance 
with the guidelines, whether as initiation, replacement, or 
as adjunctive therapy.
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